Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

Published:2017-04-10 Issue:7 Volume:19 Page:1024-1031
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Pozzilli Paolo¹,Norwood Paul²^ORCID,Jódar Esteban³⁴,Davies Melanie J.⁵^ORCID,Ivanyi Tibor⁶,Jiang Honghua⁷,Woodward D. Bradley⁷,Milicevic Zvonko⁸^ORCID

Affiliation:

1. Unit of Endocrinology and Diabetes; University Campus Bio-Medico; Rome Italy

2. Centre of Immunobiology, Barts and the London School of Medicine; Queen Mary University of London; UK

3. Valley Endocrine and Research; Fresno California

4. Hospital Universitario Quirón Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid; Madrid

5. University of Leicester; Diabetes Research Centre; Leicester UK

6. Eli Lilly and Company; Budapest Hungary

7. Eli Lilly and Company; Indianapolis Indiana

8. Eli Lilly and Company; Vienna Austria

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12937/fullpdf

Reference26 articles.

1. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients;Riddle;Diabetes Care,2003

2. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in patients with type 2 diabetes;Rosenstock;Diabetes Care,2005

3. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study;Yki-Järvinen;Diabetologia,2006

4. Body weight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus;Hermansen;Drug Saf,2007

5. What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres;Fulcher;Diabetes Res Clin Pract,2015

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials;Biomedicines;2024-08-23

2. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association;Diabetes & Metabolism Journal;2024-07-31

3. Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6);Diabetes Therapy;2024-07-15

4. Non‐insulin Parenteral Therapies;Textbook of Diabetes;2024-01-12

5. Glucagon-like Peptide-1 Agonists;JBJS Reviews;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3